1 / 8

Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2014

Global Markets Direct’s, ‘Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2014’, provides an overview of the Prader-Willi Syndrome (PWS)’s therapeutic pipeline. To Get More Info. Visit : http://www.analyzefuture.com/prader-willi-syndrome-pws-pipeline-review-h2-2014-market This report provides comprehensive information on the therapeutic development for Prader-Willi Syndrome (PWS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prader-Willi Syndrome (PWS) and special features on late-stage and discontinued projects.

angie_patterson
Télécharger la présentation

Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2014

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2014 No. Pages : 53 Published on : Dec-2014

  2. Report Description Global Markets Direct’s, ‘Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2014’, provides an overview of the Prader-Willi Syndrome (PWS)’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Prader-Willi Syndrome (PWS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prader-Willi Syndrome (PWS) and special features on late-stage and discontinued projects. To Get More Info. Visit : http://www.analyzefuture.com/prader-willi-syndrome-pws-pipeline-review-h2-2014-market Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

  3. Report Description Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. To Enquire About Report @ http://www.analyzefuture.com/prader-willi-syndrome-pws-pipeline-review-h2-2014-market/report-enquiry The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

  4. Table of Content Table Of ContentsTable of ContentsTable of Contents 2List of Tables 4List of Figures 4Introduction 5Global Markets Direct Report Coverage 5Prader-Willi Syndrome (PWS) Overview 6Therapeutics Development 7Pipeline Products for Prader-Willi Syndrome (PWS) - Overview 7Pipeline Products for Prader-Willi Syndrome (PWS) - Comparative Analysis 8Prader-Willi Syndrome (PWS) - Therapeutics under Development by Companies 9Prader-Willi Syndrome (PWS) - Pipeline Products Glance 10Late Stage Products 10Clinical Stage Products 11Early Stage Products 12Prader-Willi Syndrome (PWS) - Products under Development by Companies 13Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development 14

  5. Table of Content Chong Kun Dang Pharmaceutical Corp. 14Essentialis, Inc. 15Ferring International Center S.A. 16LG Life Sciences, Ltd. 17P2D Bioscience 18Pfizer Inc. 19Rhythm Pharmaceuticals 20Prader-Willi Syndrome (PWS) - Therapeutics Assessment 21Assessment by Monotherapy Products 21Assessment by Target 22Assessment by Mechanism of Action 24Assessment by Route of Administration 26Assessment by Molecule Type 28Drug Profiles 30beloranib - Drug Profile 30Product Description 30Mechanism of Action 30R&D Progress 30betahistine hydrochloride - Drug Profile 33

  6. Table of Content Product Description 33Mechanism of Action 33R&D Progress 33diazoxide choline CR - Drug Profile 34Product Description 34Mechanism of Action 34R&D Progress 34FE-992097 - Drug Profile 36Product Description 36Mechanism of Action 36R&D Progress 36NOX-B11 - Drug Profile 37Product Description 37Mechanism of Action 37R&D Progress 37setmelanotide - Drug Profile 38Product Description 38Mechanism of Action 38R&D Progress 38

  7. Table of Content somatropin SR - Drug Profile 39Product Description 39Mechanism of Action 39R&D Progress 39Prader-Willi Syndrome (PWS) - Recent Pipeline Updates 41Prader-Willi Syndrome (PWS) - Product Development Milestones 46Featured News & Press Releases 46Nov 14, 2014: Essentialis To Present Clinical Update At The Annual Research Conference Of The Foundation For Prader-Willi Research 46Oct 01, 2014: Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome 46Jul 23, 2014: Essentialis Secures Foundation for Prader-Willi Research Grant to Help Advance DCCR in the Treatment of Prader-Willi Syndrome 47Jul 10, 2014: Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Prader-Willi Syndrome 47 To Get Complete TOC Visit at: http://www.analyzefuture.com/prader-willi-syndrome-pws-pipeline-review-h2-2014-market/table-of-contents

  8. FOR MORE DETAILS Visit us at : http://www.analyzefuture.com/ Stay With Us: 5933 NE Win Sivers Drive, #205, Portland, OR 97220 United States. TELEPHONE: +1 (855) 711-1555 EMAIL: sales@analyzefuture.com

More Related